A patient with a spinal cord injury has become the first person to receive an experimental stem cell treatment that holds great promise for California spine injury lawyers.
California-based Geron Corporation announced this week that a patient who suffers from a spinal cord injury has received human embryonic stem cell therapy at an Atlanta center. Geron Corporation is the only company in the country with approval by the Food and Drug Administration to conduct such clinical human embryonic stem cell therapies. Geron Corporation's research into stem cell therapy is funded by private groups, which means that the company is not hindered by a recent ruling by a federal judge prohibiting the use of federal funds for human embryonic stem cell therapy research. That ruling had severely disappointed California brain injury lawyers and researchers who had pinned much hope on such clinical trials. But the federal ruling will not apply to the Geron trial.
For now, this is a phase 1 trial, which means that researchers will not be looking so much at the benefits of the therapy, as much as at whether the therapy is safe to use. The patient who is now being treated with the therapy has been admitted into Shepherd Center, which is a brain injury and spinal cord injury treatment facility in Atlanta. The Atlanta site is one of seven potential facilities across the country where patients may be enrolled during the clinical trial.
According to Geron, it has spent more than $130 million in developing stem cell therapies for the treatment of spinal cord injury. Simply put, the therapy involves injecting stem cells, which have been coaxed into becoming nerve cells, directly into the injured spinal cord. The stem cells used in the therapy are leftovers from fertility treatments. Doctors are hoping that the stem cells will allow the nerves in the damaged spinal cord area to regenerate, ultimately to allow the patient to restore movement of injured legs and arms.

Comments
Post has no comments.